A quiet revolution is brewing in the market for GLP-1 weight-loss drugs, with Viking Therapeutics (VKTX) and Roche Holdings (RHHBY) gaining ground on incumbent Novo Nordisk (NVO). The two companies have signed agreements to produce GLP-1 weight-loss drugs, which could challenge Novo Nordisk’s dominance in the market.
Viking has partnered with CordenPharma to manufacture its VK2735 drug, a potential multibillion-dollar product. Roche has teamed up with Zealand Pharma to co-develop and co-commercialize petrelintide, a hormone mimic that reduces appetite and promotes weight loss.
Despite Viking and Roche’s progress, their stocks are volatile due to the uncertainty surrounding their products’ market performance. Novo Nordisk stock has taken a hit as its competitors gain traction. Analysts caution that investors should approach these stocks with caution, considering factors such as market share, pricing, and competitive advantage.
For now, investors face a tough decision: choosing between Roche, Viking, or Eli Lilly’s (LLY) GLP-1 weight-loss drug stocks. While Viking’s prospects are uncertain, Novo Nordisk remains a more stable option with lower price-to-earnings ratios and higher dividend yields.
Source: https://www.fool.com/investing/2025/03/12/why-viking-therapeutics-and-roche-holdings-popped